Applied Biological Laboratories, maker of Biovanta, to present at American Society of Microbiology’s Clinical Virology Symposium 2024

(Press-News.org) (New York, NY, Oct. 8, 2024) – New York City-based biotechnology company Applied Biological Laboratories has been selected to present research and data from a randomized, double-blind placebo-controlled clinical trial of Biovanta and research on pipeline products at the American Society for Microbiology (ASM) Clinical Virology Symposium in Long Beach, California on October 8, 2024. Applied Bio is part of NYU Biolabs, a collaborative research facility and biotech incubator affiliated with New York University’s Langone Medical Center. Biovanta is the company’s line of over the counter and dietary supplement products designed to treat cold symptoms. The findings will also include preclinical data on novel anti-viral formulas in the company’s pipeline.

 

Applied Bio is committed to the research and development of novel, scientifically proven treatments for respiratory disease. Various treatments in the company’s pipeline are designed to strengthen immunity, target key inflammatory pathways, and sequester viruses, providing an array of novel approaches for treating respiratory infections as well as symptoms.

 

Established in 1899, and located in Washington DC, ASM is a professional life science organization composed of scientists, educators and healthcare professionals who are dedicated to promoting and advancing microbial sciences around the world.

 

Details of the presentation are as follows:

 

Title: Preventing Respiratory Infection by Strengthening the Respiratory Barrier and Controlling Inflammation

 

Poster Session: Track 1 Tuesday 105 Long Beach Convention Center Exhibit Hall A

 

Date/Time: Tuesday October 8, 2024, 4:30-6:30pm PST

 

Authors: Nazlie Latefi, PhD (presenting) Chief Scientific Officer and Pavel Pugach, PhD VP Research and Development, Applied Biological Laboratories, Inc.

 

The presentation will include results of a randomized, double-blind, placebo controlled clinical trial involving 159 participants in six US cities, which showed Biovanta significantly improved common cold symptoms including sore throat, cough, runny nose, congestion, chills, and sneezing in less than two days. Compared to placebo, Biovanta improved symptoms 60-70%. Biovanta was delivered as a throat spray with or without an aspirin tablet. Aspirin is a well-known anti-inflammatory and cyloxygenase inhibitor. As opposed to other cold products including those containing acetaminophen, pseudoephedrine, dexamethorphan, and guaifenesin, Biovanta targets inflammatory pathways underlying cold symptoms, which involve cyclooxygenase (COX) and prostaglandins. Biovanta throat spray without aspirin performed just as well against most symptoms and also includes a complex of unique anti-inflammatory ingredients. More information about Biovanta can be found at www.biovanta.com.

 

The presentation will also include results of antiviral studies against rhinovirus and influenza involving pipeline products developed by Applied Biological Laboratories. The anti-viral formulas contain natural competitive inhibitors to sequester viruses and prevent them from infecting, as well as natural bioactive molecules such as lysozyme and lactoferrin which stimulate immune modulating cytokines and control inflammation. This is a unique approach to treating respiratory infections. The Company is planning to move these candidates into clinical trials and submit an Investigational New Drug Application (IND) to the FDA in the next year.

END